NEWARK, DE — New preclinical research from CorriXR Therapeutics suggests a novel gene-editing strategy could reopen the door ...
Peer-reviewed results in Molecular Therapy Oncology show that targeted, mutation-agnostic CRISPR gene editing of NRF2 in head and neck cancer models resensitizes treatment resistant tumors to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results